Profound Medical (NASDAQ: PROF; TSX: PRN) has appointed Richard Fabian as president, effective immediately, succeeding Mathieu Burtnyk, PhD, who has assumed the newly created position of chief technology officer.
Mr. Fabian has an accomplished history of sales, marketing, operations, general and executive management success within the global healthcare industry, specifically in the medical imaging and medical device spaces. In a career spanning more than 29 years, he most recently served as chief executive officer of FUJIFILM Sonosite, an innovator and leader in point-of-care ultrasound. Before joining Sonosite, Mr. Fabian served in a variety of roles with Philips Healthcare, the primary healthcare and medical technology business segment and division of Royal Philips (NYSE: PHG, AEX: PHIA). Starting in 2002 as a Senior Director in the Cardiovascular X-ray Business Unit, North America, he progressed to lead in several executive roles in sales, marketing, and global general management. Earlier in his career, Mr. Fabian was VP, Sales at Noetix Corporation (now Magnitude Angles) and VP, Operations at STERIS Corporation.
In a statement, Arun Menawat, CEO and chairman of Profound, commented, “I am excited that we were able to recruit a medical device executive of Rich’s caliber to this key position. Rich is a seasoned leader with a strong track record of delivering profitable growth to both established and emerging healthcare businesses. I have tremendous confidence in his ability to help us sharpen our overall execution. At the same time, I am pleased that our continuing clinical innovation and development will be in the capable hands of Mathieu, the inventor of the patented closed-loop temperature feedback control algorithm used by TULSA-PRO, as well as the executive who has led the scientific design and execution of all of our clinical studies for the technology, including the ongoing Level 1 post-market CAPTAIN randomized controlled trial.”
Mr. Fabian remarked, “I am incredibly energized to join Profound at such a transformative time in the evolutions of both robotic and incisionless surgeries. By combining the unrivalled precision and patient-centered customization enabled by real-time MRI guidance and thermometry, artificial intelligence, and supervised autonomous robotics, Profound is truly changing the paradigm for patients facing prostate disease and other conditions—proving that effective treatment no longer requires compromising a patient’s quality of life. I am honored to be part of a team that is actively replacing uncertainty with clarity and expanding the boundaries of modern medicine.”
